![MiNK Therapeutics Inc](/common/images/company/N_INKT.png)
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses. MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T cell therapies to treat cancer and other life-threatening illnesses.
NEW YORK, June 05, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
NEW YORK, May 22, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of...
Completed $5.8 million private placement financing at 25% premium Upcoming presentation of agenT-797 in severe respiratory distress at the American Thoracic Society (ATS)AACR presentation reported...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.1046 | -10.8405016064 | 0.9649 | 1.24 | 0.85 | 128005 | 1.07635354 | CS |
4 | -0.0297 | -3.33707865169 | 0.89 | 1.24 | 0.83113 | 71588 | 0.99678516 | CS |
12 | -0.0397 | -4.41111111111 | 0.9 | 1.3 | 0.83113 | 158250 | 0.99145265 | CS |
26 | 0.0003 | 0.0348837209302 | 0.86 | 1.9 | 0.78 | 122592 | 1.05517308 | CS |
52 | -1.0097 | -53.9946524064 | 1.87 | 1.96 | 0.75 | 86813 | 1.12321192 | CS |
156 | -11.1797 | -92.8546511628 | 12.04 | 22.155 | 0.75 | 116596 | 2.84709528 | CS |
260 | -11.1797 | -92.8546511628 | 12.04 | 22.155 | 0.75 | 116596 | 2.84709528 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.